<DOC>
	<DOC>NCT00409461</DOC>
	<brief_summary>Proof of concept study in islet transplantation, two treatment arms (ATG SIR-TAC versus ATG SIR) each consisting of ten type 1 diabetic patients</brief_summary>
	<brief_title>Comparison of Sirolimus Alone With Sirolimus Plus Tacrolimus in Type 1 Diabetic Recipients of Cultured Islet Cell Grafts</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Type 1 insulindependent diabetic patients Cpeptide &lt; 0.15 nmol/l (&lt;0.45 Âµg/l) 6 min. after glucagon IV (1mg) (glycemia &gt; 180 mg/dl) diabetic nephropathy hypoglycaemic unawareness smoker before transplantation plasma creatinine &gt; 2 mg/dl albuminuria &gt;1000 mg/24 hrs abnormal liver function history of thrombosis or pulmonary embolism history of malignancy, tuberculosis or chronic viral hepatitis history of any other serious illness which could be relevant for the protocol HLA antibodies EBV antibody negative HIV 1 &amp; 2 antibody positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2006</verification_date>
</DOC>